List of investigational substance-related disorder drugs

This is a dynamic list and may never be able to satisfy particular standards for completeness. You can help by editing the page to add missing items, with references to reliable sources.

This is a list of investigational substance-related disorder drugs, or drugs that are currently under development for clinical use for the treatment of substance-related disorders but are not yet approved. Substance-related disorders include substance use disorders like alcoholism (alcohol use disorder), amphetamine use disorder, cocaine use disorder, nicotine use disorder, and opioid use disorder, among others. In addition, they include substance withdrawal syndromes like alcohol withdrawal and opioid withdrawal as well as substance overdoses like opioid overdose.

Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Mechanism of Action – Indication [Reference]".

This list was last comprehensively updated in January 2026. It is likely to become outdated with time.

Under development

Phase 3

• Brenipatide (LY-3537031) – glucagon-like peptide-1 (GLP-1) receptor agonist, gastric inhibitory polypeptide (GIP) receptor agonist – alcoholism ^[1]
• Ketamine (AWKN-001; AWKN-P-001) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – alcoholism ^[2]
• Naloxone intranasal (FMXIN-001; NS-001; naloxone microspheres powder nasal spray) – μ-opioid receptor antagonist – opioid-related disorders ^[3]
• Ondansetron (AD-04) – serotonin 5-HT₃ receptor antagonist – alcoholism ^[4]
• Zolpidem (ALM-006; ALM006) – GABA_A receptor positive allosteric modulator/nonbenzodiazepine – substance-related disorders ^{[5] [6]}

Phase 2/3

• Metyrapone/oxazepam (EMB-001C; EMB-001) – combination of metyrapone (11β-hydroxylase inhibitor and cortisol synthesis inhibitor) and oxazepam (benzodiazepine/GABA_A receptor positive allosteric modulator) – smoking withdrawal ^[7]
• NFL-101 (tobacco leaf extract) – immunomodulator (smoking vaccine) – smoking withdrawal ^{[8] [9] [10]}

Phase 2

• AEF-0117 – cannabinoid CB₁ receptor antagonist – substance-related disorders ^[11]
• ASP-8062 – GABA_B receptor modulator – alcoholism ^[12]
• BP-1.3656B (BP-1.3656; BP1.3656B; BP13656) – histamine H₃ receptor antagonist – alcoholism ^[13]
• BP-1.4979 (BP-1.4979; BP-14979; BP14979) – dopamine D₃ receptor partial agonist – smoking withdrawal ^[14]
• Brenipatide (LY-3537031) – glucagon-like peptide-1 (GLP-1) receptor agonist, gastric inhibitory polypeptide (GIP) receptor agonist – smoking withdrawal ^[15]
• Buprenorphine sublingual ethanol-free (CHF-6563; CHF6563) – μ-opioid receptor agonist, δ-opioid receptor agonist, κ-opioid receptor antagonist, nociceptin receptor agonist – opioid-related disorders ^{[16] [17]}
• Buprenorphine/naloxone (naloxone/buprenorphine) – combination of buprenorphine (non-selective opioid receptor modulator) and naloxone (orally/sublingually inactive opioid receptor antagonist) – opioid-related disorders ^[18]
• Bupropion/dextromethorphan (bupropion/DXM; Auvelity; AXS-05) – combination of bupropion (norepinephrine–dopamine reuptake inhibitor (NDRI), nicotinic acetylcholine receptor antagonist, CYP2D6 inhibitor) and dextromethorphan (DXM) (NMDA receptor antagonist, serotonin reuptake inhibitor, sigma receptor agonist, other actions) – smoking withdrawal ^[19]
• Bupropion/naltrexone (Contrave; CX-101; Mysimba; naltrexone/bupropion; NB32) – combination of bupropion (norepinephrine–dopamine reuptake inhibitor (NDRI), nicotinic acetylcholine receptor antagonist) and naltrexone (opioid receptor antagonist) – smoking withdrawal ^[20]
• C4X-3256 (INDV-2000) – orexin OX₁ receptor antagonist – opioid-related disorders ^[21]
• Cannabidiol (CBD; A-1002-N5S; Nantheia) – cannabinoid/various actions – opioid-related disorders, smoking withdrawal ^[22]
• Cannabidiol (CBD; Epidiolex; Epidyolex; Epidiolexa; GW-42003; GWP-42003; GWP-42003-P; JZP-926) – cannabinoid/various actions – heroin-related disorders, opioid-related disorders ^[23]
• Centanafadine (CTN-SR; EB-1020) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) – smoking withdrawal ^[24]
• Cocaine esterase (RBP-8000; TNX-1300) – enzyme replacement – cocaine-related disorders ^[25]
• Cyproheptadine/prazosin (KT-110; Periactine/Alpress) – combination of cyproheptadine (various actions) and prazosin (α₁-adrenergic receptor antagonist) – alcoholism ^[26]
• Devextinetug (anti-methamphetamine chimeric monoclonal antibody; Ch-mAb7F9; IXT-m200; METH-mAb) – immunomodulator (monocloncal antibody against methamphetamine) – substance-related disorders ^[27]
• F-652 (IL-22 IgG2 Fusion Protein; IL-22 IgG2-Fc; rhIL-22 dimer) – interleukin, immunoglobulin Fc fragment, recombinant fusion protein, anti-inflammatory, hepatoprotectant – alcoholism and alcoholic hepatitis ^[28]
• Ibudilast (AV-411; Eyevinal; Ibinal; KC-404; Ketas; MN-166; Pinatos) – phosphodiesterase PDE4 inhibitor, toll-like receptor 4 (TLR4) antagonist – alcoholism, opioid-related disorders, substance-related disorders ^[29]
• Liraglutide (LATIN-T1D; NN-2211; NN-9211; NN-8022; NNC-90-1170; Saxenda; Victoza) – glucagon-like peptide-1 (GLP-1) receptor agonist – smoking withdrawal ^[30]
• Mavoglurant (AFQ-056; STP-7) – metabotropic glutamate mGlu₅ receptor antagonist – alcoholism ^[31]
• Mazdutide (IBI-362; LY-3305677; OXM-3) – glucagon-like peptide-1 (GLP-1) receptor agonist, glucagon receptor agonist – alcoholism ^[32]
• Mebufotenin benzoate (5-MeO-DMT; BPL-002; BPL-003) – non-selective serotonin receptor agonist, serotonin 5-HT_1A and 5-HT_2A receptor agonist, serotonergic psychedelic – alcoholism ^[33]
• Metyrapone/oxazepam (EMB-001C; EMB-001) – combination of metyrapone (11β-hydroxylase inhibitor and cortisol synthesis inhibitor) and oxazepam (benzodiazepine/GABA_A receptor positive allosteric modulator) – cocaine-related disorders ^[34]
• Midomafetamine (MDMA) – serotonin–norepinephrine–dopamine releasing agent (SNDRA), serotonin 5-HT₂ receptor agonist, entactogen – alcoholism ^[35]
• Mifepristone (C-1073; Corlux; Corluxin; Korlym; Mifegyne; Mifeprex; RU-38486; RU-486) – glucocorticoid, progesterone, and androgen receptor antagonist – alcoholism ^[36]
• Miricorilant (CORT-118335) – glucocorticoid and mineralocorticoid receptor antagonist – alcoholism ^[37]
• Nadolol (INV-102; INV102) – non-selective beta blocker (β₁- and β₂ adrenergic receptor agonist) – smoking withdrawal ^[38]
• Neboglamine (nebostinel; CR-2249; XY-2401) – ionotropic glutamate glycine-gated NMDA receptor agonist – cocaine-related disorders ^[39]
• NNC0194-0499 (NN-9500; NN-9499; NNC-0194-0499) – fibroblast growth factor (FGF) receptor agonist – substance-related disorders ^[40]
• NS-2359 (GSK-372475) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) – cocaine-related disorders ^[41]
• OMS-405 (OMS405) – PPARγ agonist – opioid-related disorders, smoking withdrawal ^[42]
• Pemvidutide (ALT-801- Altimmune; SP-1373; VPD-107) – glucagon-like peptide-1 (GLP-1) receptor agonists, glucagon receptor agonist – alcoholism ^[43]
• Psilocybin (SYNP-101; synthetic psilocybin) – non-selective serotonin receptor agonist, serotonin 5-HT_2A receptor agonist, and serotonergic psychedelic – alcoholism ^[44]
• Selonabant (ANEB-001; V-24343) – cannabinoid CB₁ receptor antagonist – substance-related disorders ^[45]
• Sunobinop (IMB-115; IT-1315; RSC117957; S-117957; V-117957) – nociceptin receptor agonist – alcoholism ^[46]
• TA-CD (TA-CD; TA-CD09) – immunostimulant (cocaine vaccine) – cocaine-related disorders ^[47]
• TMP-301 (Heptares 25; HTL-0014242; HTL14242) – metabotropic glutamate mGlu₅ receptor antagonist – alcoholism ^[48]
• Zolunicant (18-methoxycoronaridine; 18-MC; MM-110) – α₃β₄ nicotinic acetylcholine receptor antagonist – opioid-related disorders ^[49]

Phase 1/2

• Dexmedetomidine (BXCL-501; Igalmi; KalmPen) – α₂-adrenergic receptor agonist – opioid-related disorders ^[50]
• Ibogaine (DMX-1002; IBX-210) – various actions/unknown mechanism of action and oneirogen/hallucinogen – opioid-related disorders ^[51]
• 5-Methoxy-2-aminoindane (MEAI; 5-MeO-AI; CMND-100) – serotonin–norepinephrine releasing agent – alcoholism ^[52]
• PT-00114 (PT100114; TCAP-1) – corticotropin-releasing hormone (CRH) inhibitor – opioid-related disorders ^[53]

Phase 1

• AZD-4041 – orexin OX₁ receptor antagonist – opioid-related disorders ^[54]
• BI-1356225 – ghrelin O-acyltransferase (GOAT) inhibitor – opioid-related disorders ^[55]
• C4X-3256 (INDV-2000) – orexin OX₁ receptor antagonist – substance-related disorders ^[56]
• Cebranopadol (GRT-6005; PRK-101; TRN-228) – μ-opioid receptor agonist, nociceptin receptor agonist – substance-related disorders ^[57]
• Dimethyltryptamine/harmine (DMT/harmine; RE-01) – combination of dimethyltryptamine (DMT) (serotonin 5-HT_2A receptor agonist and serotonergic psychedelic) and harmine (monoamine oxidase inhibitor (MAOI) and other actions) – cocaine-related disorders ^[58]
• DPI-125 (MCP-201) – μ-opioid receptor agonist, δ-opioid receptor agonist, κ-opioid receptor agonist – opioid-related disorders ^[59]
• Ibuprofen/ketotifen (SJP-005) – combination of ibuprofen (cyclooxygenase (COX) inhibitor/NSAID) and ketotifen (histamine H₁ receptor antagonist, other actions) – opioid-related disorders ^[60]
• Icalcaprant (ABBV-1354; CVL-354) – κ-opioid receptor antagonist – opioid-related disorders ^[61]
• KNX-100 (SOC-1) – oxytocin receptor modulator – opioid-related disorders, substance-related disorders ^{[62] [63] [64]}
• Mavoglurant (AFQ-056; STP-7) – metabotropic glutamate mGlu₅ receptor antagonist – cocaine-related disorders ^[65]
• MEB-1170 – μ-opioid receptor biased agonist – opioid-related disorders ^[66]
• Mebufotenin (5-MeO-DMT) – non-selective serotonin receptor agonist, serotonin 5-HT_1A and 5-HT_2A receptor agonist, and serotonergic psychedelic – substance use disorders ^[67]
• MST-01 – undefined mechanism of action – smoking withdrawal ^[68]
• Nalmefene (AV-104; TH-104) – μ-opioid receptor antagonist, κ-opioid receptor weak partial agonist – opioid-related disorders ^[69]
• Naltrexone implantable pellets (BICX-102, BICX-104) – opioid receptor antagonist – alcoholism, opioid-related disorders, substance-related disorders ^[70]
• Noribogaine (DMX-1001) – various actions – alcoholism ^[67]
• NRS-033 (nalmefene prodrug) – μ-opioid receptor antagonist, κ-opioid receptor weak partial agonist – opioid-related disorders ^[71]
• OMS-527 (OMS-182399; OMS527) – phosphodiesterase PDE7 inhibitor – cocaine-related disorders ^[72]
• Psilocybin (MLS-101/MLS101) – non-selective serotonin receptor agonist, serotonin 5-HT_2A receptor agonist, serotonergic psychedelic – opioid-related disorders ^{[73] [67]}
• Smoking cessation therapeutics - Astraea Therapeutics – nicotinic acetylcholine receptor antagonists – smoking withdrawal ^[74]
• SXC-2023 – cystine/glutamate transporter (SLC7A11) – cocaine-related disorders ^[75]
• Tezampanel (LY-293558; NGX-424; PRN-001-01) – ionotropic glutamate AMPA and kainate receptor antagonist – opioid-related disorders ^[76]
• TMP-301 (Heptares 25; HTL-0014242; HTL14242) – metabotropic glutamate mGlu₅ receptor antagonist – cocaine-related disorders, substance-related disorders ^[77]

Preclinical

• AM-510 – undefined mechanism of action – opioid-related disorders ^[78]
• ATI-1013 – monoclonal antibody against nicotine – smoking withdrawal ^[79]
• CTRX-1001 – immunostimulant – opioid-related disorders ^[80]
• CTRX-2001 – immunostimulant – opioid-related disorders ^[81]
• Cyclobenzaprine (KRL-102; TNX-102; Tonmya; VLD-cyclobenzaprine) – tricyclic antidepressant (various actions) – alcoholism ^[82]
• Cyproheptadine/prazosin (KT-110; Periactine/Alpress) – combination of cyproheptadine (various actions) and prazosin (α₁-adrenergic receptor antagonist) – cocaine-related disorders ^[83]
• Dimethyltryptamine (DMT; EBRX-101) – non-selective serotonin receptor agonist, serotonin 5-HT_2A receptor agonist, and serotonergic psychedelic – alcoholism ^[84]
• EQL-101 – undefined mechanism of action (non-hallucinogenic non-cardiotoxic ibogaine derivative) – substance use disorders ^{[67] [85]}
• Flumazenil/naloxone transdermal patch (MX-1607; RescuePatch) – combination of flumazenil (GABA_A receptor negative allosteric modulator/benzodiazepine antagonist) and naloxone (opioid receptor antagonist) – substance-related disorders ^[86]
• GM-3009 – κ-opioid receptor agonist (noribogaine analogue) – opioid-related disorders ^[87]
• INDV-1000 (GABA_B PAM) – GABA_B receptor positive allosteric modulator – substance-related disorders ^[88]
• LPH-48 – undefined mechanism of action and serotonergic psychedelic ((shorter-acting LPH-5 analogue) – alcoholism ^{[89] [90] [91] [67]}
• M-101 – GABA receptor antagonist – substance-related disorders ^[92]
• 5-Methoxy-2-aminoindane (MEAI; 5-MeO-AI; CMND-100) – serotonin–norepinephrine releasing agent – cocaine-related disorders ^[93]
• Metyrapone/oxazepam (EMB-001C; EMB-001) – combination of metyrapone (11β-hydroxylase inhibitor and cortisol synthesis inhibitor) and oxazepam (benzodiazepine/GABA_A receptor positive allosteric modulator) – substance-related disorders ^[94]
• Midomafetamine microneedle transdermal patch (MDMA; ecstasy) – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT₂ receptor agonist, entactogen – substance-related disorders ^[95]
• Naltrexone controlled-release (BICX101, BICX-101) – opioid receptor antagonist – alcoholism, opioid-related disorders ^[96]
• Nicotine degrading enzyme (ATI-3009; NicA2; NicA2-J1) – enzyme – smoking withdrawal ^[97]
• PPL-138 (BU10038, BU-10038) – nociceptin receptor agonist, μ-opioid receptor agonist, opioid peptide agonist – alcoholism, cocaine-related disorders ^[98]
• PSIL-001 (DMT analogue) – non-hallucinogenic serotonin 5-HT₁ receptor modulator – substance-related disorders ^{[99] [100]}
• PSIL-002 (DMT analogue) – non-hallucinogenic serotonin 5-HT₁ receptor modulator – substance-related disorders ^{[101] [100] [102]}
• Psilacetin (O-acetylpsilocin; 4-AcO-DMT) – non-selective serotonin receptor agonist, serotonin 5-HT_2A receptor agonist, serotonergic psychedelic – substance-related disorders ^[103]
• Pudafensine (IP-2015; IP-2017; IPNP-2015; IPTN-2021) – serotonin–norepinephrine–dopamine reuptake inhibitor – substance-related disorders ^[104]
• Research programme: psychedelic-based neurological therapeutics - Psilera – undefined mechanism of action and serotonergic psychedelics – alcoholism ^[105]
• Research programme: psychoplastogen therapeutics - Collaborations Pharmaceuticals – undefined mechanism of action – opioid-related disorders ^[106]
• TACT411 – serotonin 5-HT_1B receptor modulator and monoamine transporter modulator – alcoholism ^{[67] [107]}
• TACT523 – undefined mechanism of action – alcoholism ^[107]
• TACT833 – serotonin 5-HT_1B receptor modulator and monoamine transporter modulator – alcoholism ^{[67] [107]}
• VS-01 (VS-01-HAC) – ammonia scavenger – substance-related disorders ^[108]

Research

• AM-1006 – undefined mechanism of action (short-acting subperceptual psychoactive drug) – substance use disorders ^{[67] [109]}
• Ibogaine – various actions, oneirogen/hallucinogen – substance-related disorders ^[110]
• Mebufotenin (5-MeO-DMT; LSR-2000) – non-selective serotonin receptor agonist, serotonin 5-HT_1A and 5-HT_2A receptor agonist, serotonergic psychedelic – alcoholism ^[111]
• MYCO-004 (patch-delivered tryptamine compound) – undefined mechanism of action, serotonergic psychedelic – smoking withdrawal, substance-related disorders ^{[112] [113] [114]}
• Research programme: Ibogaine derivatives - MindMed/Nextage Therapeutics – various actions – opioid-related disorders ^[115]
• Research programme: monoclonal antibody therapeutics - CounterX Therapeutics – undefined mechanism of action – opioid-related disorders ^[116]
• Research programme: psychedelic and empathogenic compounds subcutaneous - Bexson Biomedical – undefined mechanism of action – substance-related disorders ^[117]
• Substance-related disorders therapeutics - Tessara Therapeutics/Xylo Bio/University of Sydney – neuronal plasticity modulators – substance-related disorders ^[118]
• VVZ-2471 – metabotropic glutamate mGlu₅ receptor antagonist, serotonin 5-HT_2A receptor antagonist – opioid-related disorders ^[119]

Clinical phase unknown

• Nicotine orally-dissolving film (NAL-2762) – nicotinic acetylcholine receptor agonist – smoking withdrawal ^[120]

Phase unknown

• AP-002 (AP002) – undefined mechanism of action – opioid-related disorders ^[121]
• AP-005 (AP005) – undefined mechanism of action – opioid-related disorders ^[122]
• Varenicline implant (SK-2109) – nicotinic acetylcholine receptor agonist – smoking withrawal ^[123]

Not under development

No development reported

• AD-6626 – aldehyde dehydrogenase 2 (ALDH2) inhibitor – alcoholism ^[124]
• AM-6527 (AM6527) – cannabinoid CB₁ receptor antagonist – substance-related disorders ^[125]
• Amitifadine (DOV-21947; EB-1010) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) – alcoholism, opioid-related disorders, smoking withdrawal, substance-related disorders ^[126]
• Arbaclofen extended release – GABA_B receptor agonist – opioid-related disorders ^[127]
• BMB-101 – serotonin 5-HT₂ receptor agonist – opioid-related disorders ^[128]
• Bupropion/mecamylamine (INT-0003; QuitPak) – combination of bupropion (norepinephrine–dopamine reuptake inhibitor (NDRI), nicotinic acetylcholine receptor negative allosteric modulator) and mecamylamine (non-selective nicotinic acetylcholine receptor antagonist) – smoking withdrawal ^[129]
• Cannabidiol (CBD; cannabidiol transderma/topical gel/patch; Zygel; ZYN-002) – cannabinoid/various actions – alcoholism, substance-related disorders ^[130]
• CM-1212 – undefined mechanism of action – alcoholism, substance-related disorders ^[131]
• CPP-115 – GABA transaminase (GABA-T) inhibitor – substance-related disorders ^[132]
• CT-044 analogues - CERSCI Therapeutics – reactive oxygen species (ROS) inhibitors (CT-044 analogues) – opioid-related disorders ^[133]
• CX-717 (CX717) – AMPA receptor positive allosteric modulator (ampakine) – substance-related disorders ^[134]
• Cyproheptadine/prazosin (KT-110; Periactine/Alpress) – combination of cyproheptadine (various actions) and prazosin (α₁-adrenergic receptor antagonist) – substance-related disorders ^[135]
• DCR-AUD (DCR-A1203; NN-6020) – aldehyde dehydrogenase 2 (ALDH2) inhibitor, RNA interference – alcoholism ^[136]
• Dimethyltryptamine (DMT; EBRX-101) – non-selective serotonin receptor agonist, serotonin 5-HT_2A receptor agonist, and serotonergic psychedelic – smoking withdrawal ^[137]
• GLWL-01 – ghrelin O-acyltransferase (GOAT) inhibitor – alcoholism ^[138]
• GSK-598809 (GSK598809) – dopamine D₃ receptor antagonist – smoking withdrawal, substance-related disorders ^[139]
• GSK-1521498 – μ-opioid receptor inverse agonist – cocaine-related disorders ^[140]
• GTS-21 (DMXB-A; DMBX-anabaseine) – nicotinic acetylcholine receptor agonist – smoking withdrawal ^[141]
• Icalcaprant (ABBV-1354; CVL-354) – κ-opioid receptor antagonist – substance-related disorders ^[142]
• Levodopa (CVT-301; CXG-89; Inbrija) – dopamine precursor (non-selective dopamine receptor agonist) – smoking withdrawal ^[143]
• Mazindol controlled release (NLS-0; NLS-1; NLS-10; NLS-13; NLS-2; Nolazol; Quilience) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) – opioid-related disorders ^[144]
• Midomafetamine (MDMA; ecstasy) – serotonin–norepinephrine–dopamine releasing agent (SNDRA), serotonin 5-HT₂ receptor agonist, and entactogen – substance-related disorders ^[145]
• Mifepristone (C-1073; Corlux; Corluxin; Korlym; Mifegyne; Mifeprex; RU-38486; RU-486) – glucocorticoid, progesterone, and androgen receptor antagonist – smoking withdrawal ^[146]
• Modafinil oral (ASB) – atypical dopamine reuptake inhibitor (DRI) – cocaine-related disorders ^[147]
• Naloxone nasal spray (-12; LT-20; LT-21; LT-22; Naloxon B; Narcan Nasal Spray; OPNT-001) – μ-opioid receptor antagonist – cocaine-related disorders, substance-related disorders ^[148]
• Nalmefene implant (nalmefene six-month implant) – μ-opioid receptor antagonist, κ-opioid receptor weak partial agonist – opioid-related disorders ^[149]
• Naloxone buccal/intransal gel (Exonal) – opioid receptor antagonist – opioid-related disorders ^[150]
• Nicotine abuse vaccine (Niccine) – nicotinic acetylcholine receptor agonist – smoking withdrawal ^[151]
• Nicotine/cannabidiol chewing gum (nicotine/CBD; CVSI-007) – combination of nicotine (nicotinic acetylcholine receptor agonist) and cannabidiol (CBD) (cannabinoid/various actions) – smoking withdrawal ^[152]
• Noribogaine derived therapeutic – various actions (noribogaine derivative) – opioid-related disorders ^[153]
• OMS-405 (OMS405) – PPARγ agonist – alcoholism ^[154]
• Ondansetron (AD-04) – serotonin 5-HT₃ receptor antagonist – opioid-related disorders, smoking withdrawal ^[155]
• Ondansetron/topiramate (AD-01; AD/TO-01) – combination of ondansetron (serotonin 5-HT₃ receptor antagonist) and topiramate (various actions) – alcoholism ^[156]
• Ondelopran (LY-2196044; Odelepan; Odelepran; OpRA) – opioid receptor antagonist – alcoholism ^[157]
• PF-5402536 (NIC7-001; PF-5402536) – immunostimulant (smoking vaccine) – smoking withdrawal ^[158]
• Pomaglumetad methionil (DB103; LY-2140023; LY-2812223; LY-404039 prodrug) – metabotropic glutamate mGlu₂ and mGlu₃ receptor receptor agonist (pomaglumetad prodrug) – substance-related disorders ^[159]
• PPL-103 – μ-opioid receptor agonist, δ-opioid receptor agonist, κ-opioid receptor agonist – substance-related disorders ^[160]
• Pregnenolone methyl ether (3β-methoxypregnenolone; MAP-4343) – microtubule-associated protein (MAP) stimulant and tubulin polymerization promoter – substance-related disorders ^[161]
• Psilocybin (MYCO-001; MYCO-003) – non-selective serotonin receptor agonist, serotonin 5-HT_2A receptor agonist, and serotonergic psychedelic – substance-related disorders ^[162]
• PT-150 (PT150; ORG-34517; SCH-900636) – androgen and glucocorticoid receptor antagonist – alcoholism ^[163]
• Research programme: alcoholism therapeutics - ADial Pharmaceuticals – various actions – alcoholism ^[164]
• Research programme: allosteric modulators - Addex Therapeutics – various actions – substance-related disorders ^[165]
• Research programme: GPCR modulators - Nxera Pharma – various actions – cocaine-related disorders, substance-related disorders ^[166]
• Research programme: nociceptin receptor agonists - Astraea Therapeutics – nociceptin receptor agonist, opioid receptor agonist – alcoholism, substance-related disorders ^[167]
• Research programme: smoking cessation therapies - Ophidion – smoking withdrawal – nicotinic acetylcholine receptor agonists ^[168]
• Research programme: tryptamine based therapeutics - PsyBio Therapeutics – serotonin 5-HT_2A receptor agonists – substance-related disorders ^[169]
• Saracatinib (AZD-0530) – Src-family kinase inhibitor – alcoholism ^[170]
• SBP-9330 – metabotropic glutamate mGlu₂ receptor modulator – smoking withdrawal ^[171]
• SEL-068 (tSVP; immunomodulatory nanoparticle vaccine for smoking cessation) – immunomodulator (smoking vaccine) – smoking withdrawal ^[172]
• Serdexmethylphenidate (KP-484; KP-1077; KP-1077H; KP-1077IH; KP-1077N; KP-879) – norepinephrine–dopamine reuptake inhibitor (NDRI) (dexmethylphenidate prodrug) – substance-related disorders ^[173]
• TRV-734 (TRV734) – μ-opioid receptor biased agonist – opioid-related disorders ^[174]
• VDM-001 – opioid receptor antagonist – alcoholism, opioid-related disorders ^[175]
• Zolunicant (18-methoxycoronaridine; 18-MC; MM-110) – α₃β₄ nicotinic acetylcholine receptor antagonist – substance-related disorders ^[176]

Suspended

• Dexmedetomidine (BXCL-501; Igalmi; KalmPen) – α₂-adrenergic receptor agonist – alcoholism ^[177]
• Tetrodotoxin (9401-TTX; Halneuron; Tectin; Tetrodin; Tocudin) – voltage-gated sodium channel blocker ^[178]

Discontinued

• ABT-436 – vasopressin V_1b receptor antagonist – alcoholism ^[179]
• Adrogolide (ABT-431; DAS-431) – dopamine D₁ receptor agonist – cocaine-related disorders ^[180]
• ADX-629 – aldehyde inhibitor / reactive aldehyde species (RASP) inhibitor – alcoholism, alcoholic hepatitis ^[181]
• ADX-10061 (CEE-310; CEE-03-310; NNC-010687; NNC-687) – dopamine D₁ receptor antagonist – smoking withdrawal, substance-related disorders ^[182]
• Anatabine (RCP-006) – nicotinic acetylcholine receptor agonist – smoking withdrawal ^[183]
• ANS-6637 (GS-6637; GS-6673) – aldehyde dehydrogenase 2 (ALDH2) inhibitor – alcoholism, opioid-related disorders, smoking withdrawal, substance-related disorders ^[184]
• Arbaclofen placarbil (R-baclofen placarbil; XP-19986) – GABA_B receptor agonist – alcoholism ^[185]
• ASP-8062 – GABA_B receptor modulator – opioid-related disorders ^[186]
• Aticaprant (AVTX-501; CERC-501; JNJ-3964; JNJ-67953964; JNJ-67953964-AAA; LY-2456302) – κ-opioid receptor antagonist – alcoholism, cocaine-related disorders, smoking withdrawal ^[187]
• Azasetron (nazasetron; Serotone; Y-25130) – serotonin 5-HT₃ receptor antagonist – cocaine-related disorders ^[188]
• AZD-4041 – orexin OX₁ receptor antagonist – smoking withdrawal ^[189]
• Baclofen/samidorphan (ALKS-29; ALKS-33/baclofen; baclofen/ALKS-33) – combination of baclofen (GABA_B receptor agonist) and samidorphan (μ-opioid receptor antagonist) – alcoholism ^[190]
• Befloxatone (MD-370503) – monoamine oxidase A (MAO-A) inhibitor – smoking withdrawal ^[191]
• BP-897 – dopamine D₃ receptor agonist – cocaine-related disorders ^[192]
• BR-9003 (BR-9003A) – undefined mechanism of action – smoking withdrawal ^[193]
• BTRX-246040 (LY-2940094) – nociceptin receptor agonist – alcoholism ^[194]
• Buprenorphine/naloxone (NanoBUP; NTC-0510; NTC-510) – combination of buprenorphine (non-selective opioid receptor modulator) and naloxone (orally/sublingually inactive opioid receptor antagonist) – opioid-related disorders ^[195]
• Buprenorphine/samidorphan (ALKS 33-BUP; ALKS 33/buprenorphine; ALKS-5461; BUP-ALKS 33; buprenorphine/ALKS-33; buprenorphine/RDC 0313; RDC 0313/buprenorphine; samidorphan/buprenorphine) – combination of buprenorphine (non-selective opioid receptor modulator) and samidorphan (μ-opioid receptor antagonist) – cocaine-related disorders ^[196]
• Cannabidiol (CBD; synthetic cannabidiol; RAD-011) – cannabinoid/various actions – substance-related disorders ^[197]
• CVL-936 – dopamine D₂ and D₃ receptor antagonist – substance-related disorders ^[198]
• CX-1739 – AMPA receptor positive allosteric modulator (ampakine) – substance-related disorders ^[199]
• CYB-003 (HLP-003; CYB003; deuterated psilocin) – non-selective serotonin receptor agonist, serotonin 5-HT_2A receptor agonist, and serotonergic psychedelic – alcoholism ^[200]
• CYB-004 (HLP-004; CYB004; deuterated dimethyltryptamine; dDMT) – non-selective serotonin receptor agonist, serotonin 5-HT_2A receptor agonist, and serotonergic psychedelic – substance-related disorders ^[201]
• Dianicline (SSR-591813) – nicotinic acetylcholine receptor agonist – smoking withdrawal ^[202]
• Drinabant (AVE-1625; INDV-5004; OPNT-004) – cannabinoid CB₁ receptor antagonist – substance-related disorders ^[203]
• Ecopipam (EBS-101; PSYRX-101; SCH-39166) – dopamine D₁ receptor antagonist – cocaine-related disorders ^[204]
• Eglumetad (eglumegad; LY-354740) – metabotropic glutamate mGlu₂ and mGlu₃ receptor agonist – smoking withdrawal ^[205]
• Elinzanetant (BAY-3427080; GSK-1144814A; GSK-1144814; Lynkuet; NT-814) – neurokinin NK₁ and NK₃ receptor antagonist – opioid-related disorders ^[206]
• Femoxetine (femoxitine; FG-4963; Malexil; NNC-204963) – selective serotonin reuptake inhibitor (SSRI) – alcoholism ^[207]
• Gabapentin enacarbil (ASP8825; Gabapentin-XP; GSK-1838262; Horizant; Regnite; Solzira; XP13512) – gabapentinoid (α₂δ subunit-containing voltage-gated calcium channel blocker) – alcoholism ^[208]
• Gepirone (Ariza; BMY-13805; Exxua; MJ-13805; Org-33062; TGFK07AD; Travivo; Variza) – serotonin 5-HT_1A receptor agonist – cocaine-related disorders ^[209]
• Istradefylline (KW-6002; Nourianz; Nouriast) – adenosine A₂ receptor antagonist ^[210]
• ITI-333 – serotonin 5-HT_2A receptor antagonist, dopamine D₁ receptor antagonist, α_1A-adrenergic receptor antagonist, μ-opioid receptor partial agonist – substance-related disorders ^[211]
• JNJ-39393406 – α₇ subunit-containing nicotinic acetylcholine receptor positive allosteric modulator – smoking withdrawal ^[212]
• JZP-150 – fatty acid amide hydrolase (FAAH) inhibitor – alcoholism ^[213]
• Lisdexamfetamine (LDX; Elvanse; NRP-104; S-877489; SHP-489; SPD-489; Tyvense; Venvanse; Vyvanse) – norepinephrine–dopamine releasing agent (NDRA) – cocaine-related disorders ^[214]
• Lorcaserin (APD-356; Belviq; E2023; Venespri) – serotonin 5-HT_2C receptor agonist – smoking withdrawal ^[215]
• Manifaxine (BW-1555U88; GW-320659) – norepinephrine–dopamine reuptake inhibitor (NDRI) – smoking withdrawal ^[216]
• Mavoglurant (AFQ-056; STP-7) – metabotropic glutamate mGlu₅ receptor antagonist – smoking withdrawal ^[217]
• Nalmefene (CPH-101; JF-1; Lu AA36143; Nalmetrene; NIH-10365; ORF-11676; Selincro; Soberal) – μ-opioid receptor antagonist, κ-opioid receptor weak partial agonist – smoking withdrawal ^[218]
• Nepicastat oral (APL-1401; SYN-117) – dopamine β-hydroxylase (DBH) inhibitor – cocaine-related disorders ^[219]
• Neramexane (KRP-209; MRZ-2/579) – NMDA receptor antagonist, nicotinic acetylcholine receptor antagonist – alcoholism ^[220]
• NIC-002 (NIC002; CYT002-NicQβ; Nicotine-Qβ) – immunostimulant (nicotine vaccine) – smoking withdrawal ^[221]
• NicVAX – immunostimulant (nicotine vaccine) – smoking withdrawal ^{[222] [223]}
• Nornicotine – nicotinic acetylcholine receptor agonist – smoking withdrawal ^[224]
• NS-2359 (GSK-372475) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) – alcoholism ^[225]
• NYX-783 – ionotropic glutamate NMDA receptor modulator – alcoholism, opioid-related disorders ^[226]
• OREX-1019 – μ-opioid receptor agonist, δ-opioid receptor antagonist, κ-opioid receptor antagonist, nociceptin receptor agonist – cocaine-related disorders ^[227]
• OREX-1038 – μ-opioid receptor agonist – cocaine-related disorders, opioid-related disorders ^[228]
• Oxytocin intranasal (Syntocinon Nasal Spray; TUR-001) – oxytocin receptor agonist – alcoholism ^[229]
• Quetiapine (FK-949; FK949E; ICI-204636; Seroquel) – atypical antipsychotic (non-selective monoamine receptor modulator) – alcoholism ^[230]
• Rimonabant (Acomplia; SR-141716; SR-141716A; Zimulti) – cannabinoid CB₁ receptor antagonist – smoking withdrawal ^[231]
• Risperidone (JNJ-410397-AAA; R-64766; R064766; Risperdal; Risperdal Consta; Risperdal Depot) – atypical antipsychotic (non-selective monoamine receptor modulator) – substance-related disorders ^[232]
• RTI-113 – dopamine reuptake inhibitor (DRI) (cocaine analogue) – cocaine-related disorders ^[233]
• Samidorphan (ALKS-33; RDC-0313; RDC-0313-00) – μ-opioid receptor antagonist – alcoholism, substance-related disorders ^[234]
• Sembragiline (EVT-302; RG-1577; RO-4602522) – monoamine oxidase B (MAO-B) inhibitor – smoking withdrawal ^[235]
• Serlopitant (JTS-661; MK-0594; VPD-737) – neurokinin NK₁ receptor antagonist – alcoholism ^[236]
• Surinabant (SR-147778; SR147778) – cannabinoid CB₁ receptor antagonist – alcoholism, smoking withdrawal ^[237]
• TA-NIC – immunostimulant (nicotine vaccine) – smoking withdrawal ^[238]
• Tradipitant (LY-686017; Nereus; VLY-686) – neurokinin NK₁ receptor antagonist – alcoholism ^[239]
• Verucerfont (GSK-561679; NBI-77860) – corticotropin-releasing factor 1 (CRF₁) receptor antagonist ^[240]
• Vigabatrin (γ-vinyl-GABA; gamma-vinyl-GABA; GVG; M071754; MDL-71754; RMI-71754; Sabril; Sabrilex) – GABA transaminase (GABA-T) inhibitor – cocaine-related disorders, substance-related disorders ^[241]

Other related drugs

• 5-Chloro-AMT (PAL-542) – serotonin–dopamine releasing agent (SDRA), serotonin receptor agonist, and monoamine oxidase A (MAO-A) inhibitor ^[242]
• 5-Fluoro-AMT (PAL-212; PAL-544) – serotonin–norepinephrine–dopamine releasing agent (SNDRA), serotonin receptor agonist, and monoamine oxidase A (MAO-A) inhibitor ^[242]
• Methocinnamox (MCAM) – long-lasting irreversible μ-opioid receptor antagonist ^{[243] [244]}
• Methoclocinnamox (MCCAM; NIH-10420) – long-lasting irreversible μ-opioid receptor partial agonist ^[245]
• Oxa-noribogaine – atypical κ-opioid receptor agonist (noribogaine analogue) ^{[246] [247]}
• SR-17018 (SR17018; SR-17; SR17; SR) – μ-opioid receptor biased agonist ^{[248] [249] [250]}

Clinically used drugs

Approved drugs

Opioid receptor modulators

• Buprenorphine depot (Brixadi; Buvidal; CAM-2038; CAM-2048) – μ-opioid receptor agonist, δ-opioid receptor agonist, κ-opioid receptor antagonist, and nociceptin receptor agonist – opioid-related disorders ^[251]
• Buprenorphine extended-release (Atrigel buprenorphine; BUP-XR-Indivior; depot buprenorphine; RBP-6000; Sublocade; Subutex prolonged release) – μ-opioid receptor agonist, δ-opioid receptor agonist, κ-opioid receptor antagonist, and nociceptin receptor agonist – opioid-related disorders ^[252]
• Buprenorphine/naloxone sublingual (naloxone/buprenorphine; Sai Bo Song; SCH-000484; Suboxone) – combination of buprenorphine (non-selective opioid receptor modulator) and naloxone (orally/sublingually inactive opioid receptor antagonist) – opioid-related disorders ^[253]
• Methadone (Zoryon) – μ-opioid receptor agonist – opioid-related disorders ^[254]
• Nalmefene (Revex) – μ-opioid receptor antagonist, κ-opioid receptor weak partial agonist – opioid overdose, alcoholism
• Nalmefene (CPH-101; JF-1; Lu AA36143; nalmetrene; NIH-10365; ORF-11676; Selincro; Soberal) – μ-opioid receptor antagonist, κ-opioid receptor weak partial agonist – alcoholism ^[255]
• Nalmefene nasal spray (intranasal nalmefene; Indivior; OPNT-003; Opvee) – μ-opioid receptor antagonist, κ-opioid receptor weak partial agonist – opioid-related disorders ^[256]
• Nalorphine (Lethidrone, Nalline) – μ-opioid receptor antagonist, κ-opioid receptor agonist – opioid overdose
• Naloxone injection (Evzio; naloxone auto injector) – opioid receptor antagonist – opioid-related disorders ^[257]
• Naloxone intranasal spray (Rezenopy) – μ-opioid receptor antagonist – opioid-related disorders ^[258]
• Naloxone intranasal spray (Kloxxado; naloxone nasal spray) μ-opioid receptor antagonist – opioid-related disorders ^[259]
• Naloxone multidose nasal spray (AP-003; Narcan) – μ-opioid receptor antagonist – opioid-related disorders ^[260]
• Naloxone nasal spray (-12; LT-20; LT-21; LT-22; Naloxon B; Narcan Nasal Spray; OPNT-001) – μ-opioid receptor antagonist – opioid-related disorders ^[261]
• Naltrexone controlled-release (Vivitrex; Vivitrol; XL-NTX; XR-NTX; ALKS-6428) – opioid receptor antagonist – alcoholism, opioid-related disorders ^[262]
• Naltrexone oral (Nalorex; Nemexin; Revia) – opioid receptor antagonist – alcoholism, opioid-related disorders ^[263]
• Other opioids (opioid agonist therapy) (e.g., dihydrocodeinone, extended-release morphine) – μ-opioid receptor agonists – opioid use disorder
• Tianeptine (Coaxil; Stablon; Tatinol) – μ-opioid receptor agonist, other actions – alcoholism ^[264]

Nicotinic acetylcholine receptor modulators

• Bupropion (amfebutamone; Aplenzin; BVF-033; Elontril; Quomem; Wellbutrin; Zyban) – norepinephrine–dopamine reuptake inhibitor (NDRI), nicotinic acetylcholine receptor negative allosteric modulator – smoking withdrawal ^[265]
• Cytisinicline (cytisine; Desmoxan; Tabex) – nicotinic acetylcholine receptor agonist – smoking withdrawal ^[266]
• Varenicline (Champix; Chantix; CP-526,555; CP-526555-18) – nicotinic acetylcholine receptor agonist – smoking withdrawal ^[267]

Other drugs

• Acamprosate (Alcomed; Aotal; calcium acetylhomotaurinate; Campral; Campral EC; NS-11; Regtect; Sobriol; Zulex) – various actions – alcoholism ^[268]
• Baclofen (Baclocur) – GABA_B receptor agonist – alcoholism ^[269]
• Calcium carbimide (Temposil) – aldehyde dehydrogenase 2 (ALDH2) inhibitor – alcoholism
• Cyanamide – aldehyde dehydrogenase 2 (ALDH2) inhibitor – alcoholism
• Disulfiram (Antabuse, Antabus) – aldehyde dehydrogenase 2 (ALDH2) inhibitor – alcoholism
• Flumazenil (flumazepil; Anexate) – GABA_A receptor negative allosteric modulator/benzodiazepine antidote – benzodiazepine overdose
• Lofexidine (BA-168; BritLofex; Lucemyra; MDL-14042; MDL-14042A; RMI-14042A) – α₂-adrenergic receptor agonist – opioid-related disorders ^[270]
• Sodium oxybate (Alcover; SMO immediate release formulation) – GABA_B and GHB receptor agonist – alcoholism ^[271]

Off-label drugs

• α₂-Adrenergic receptor agonists (e.g., clonidine, dexmedetomidine, guanfacine) – opioid withdrawal ^{[272] [273]}
• Benzodiazepines (e.g., diazepam) – GABA_A receptor positive allosteric modulators – alcohol withdrawal syndrome ^[274]
• Gabapentinoids (e.g., gabapentin, pregabalin) – α₂δ subunit-containing voltage-gated calcium channel blockers – alcohol withdrawal syndrome ^[275]
• Ibogaine ( Tabernanthe iboga ) – various actions, oneirogen/hallucinogen – opioid use disorder ^[276]
• Lobeline – nicotinic acetylcholine receptor agonist – smoking withdrawal ^[277]
• Mecamylamine – nicotinic acetylcholine receptor antagonist – smoking withdrawal ^{[278] [279]}
• Nicotine (nicotine replacement therapy; e.g., nicotine gum, nicotine inhaler, nicotine lozenge, nicotine nasal spray, nicotine patch) – nicotinic acetylcholine receptor agonist – smoking withdrawal ^[279]
• Phenibut (Anvifen) – GABA_B receptor agonist and gabapentinoid (α₂δ subunit-containing voltage-gated calcium channel blocker) – alcoholism and alcohol withdrawal syndrome ^[280]
• Serotonergic psychedelics (e.g., psilocybin, LSD, mescaline, DMT) – serotonin 5-HT_2A receptor agonists and psychedelic hallucinogens – various substance use disorders ^{[281] [282] [283]}
• Topiramate (Topamax) – various actions – alcoholism and alcohol withdrawal syndrome ^[284]

See also

• List of investigational drugs

References

1. Brenipatide - Eli Lily and Company - AdisInsight
2. Ketamine - Awakn Life Sciences - AdisInsight
3. Naloxone hydrochloride intranasal - Nasus Pharma - AdisInsight
4. Ondansetron - ADial Pharmaceuticals - AdisInsight
5. ALM 006 - AdisInsight
7. Metyrapone/oxazepam - Embera - AdisInsight
8. NFL 101 - AdisInsight
9. Goutal S, Tran T, Leroy C, Benhamouda N, Leterrier S, Saba W, Lafont B, Tartour É, Roelens M, Tournier N (July 2024). "Brain Glucose Metabolism as a Readout of the Central Nervous System Impact of Cigarette Smoke Exposure and Withdrawal and the Effects of NFL-101, as an Immune-Based Drug Candidate for Smoking Cessation Therapy". ACS Chem Neurosci. 15 (13): 2520–2531. doi:10.1021/acschemneuro.4c00204. PMID   38875216.
10. Lafay-Chebassier C, Girodet PO, Laine F, Allain JS, Pickering G, Latreille M, Demina A, Chevassus H, Ingrand I, Tartour E, Benhamouda N, Fraisse ML, Chamitava L, Plétan Y, Balland J, Donazzolo Y, Lafont B (August 2025). "Efficacy and Safety of NFL-101 as a Smoking Cessation Therapy: A Randomized Phase II Clinical Trial CESTO2". Nicotine Tob Res ntaf181. doi:10.1093/ntr/ntaf181. PMID   40884488.
11. AEF 0117 - AdisInsight
12. ASP 8062 - AdisInsight
13. BP 1.3656B - AdisInsight
14. BP 14979 - AdisInsight
15. Brenipatide - Eli Lily and Company - AdisInsight
16. CHF 6563 - AdisInsight
17. Kraft WK, Barneschi I, Bocchi M, Santoro D, Cella M (2024). "The Bioavailability of CHF6563, an Ethanol-Free, Sublingual Neonatal Buprenorphine Formulation: A Bridging Study Conducted in Adults". J Pediatr Pharmacol Ther. 29 (1): 49–52. doi:10.5863/1551-6776-29.1.49. PMC   10849686 . PMID   38332965.
18. Buprenorphine/naloxone - Aoxing Pharmaceutical Company - AdisInsight
19. Bupropion/dextromethorphan - Axsome Therapeutics - AdisInsight
20. Bupropion/naltrexone - Currax Pharmaceuticals - AdisInsight
21. C4X 3256 - AdisInsight
22. Cannabidiol - ANANDA Scientific - AdisInsight
23. Cannabidiol - GW Pharmaceuticals - AdisInsight
24. Centanafadine - Otsuka Pharmaceutical - AdisInsight
25. Cocaine esterase - Tonix Pharmaceuticals Holding Corp - AdisInsight
26. Cyproheptadine/Prazosin - Kinnov Therapeutics - AdisInsight
27. Devextinetug - InterveXion Therapeutics - AdisInsight
28. F 652 - AdisInsight
29. Ibudilast - MediciNova - AdisInsight
30. Liraglutide - Novo Nordisk - AdisInsight
31. Mavoglurant - STALICLA - AdisInsight
32. Mazdutide - Eli Lilly and Company - AdisInsight
33. Mebufotenin benzoate- Atai Beckley - AdisInsight
34. Metyrapone/oxazepam - Embera - AdisInsight
35. Methylenedioxymetamfetamine - MAPS Europe B.V. - AdisInsight
36. Mifepristone - Corcept Therapeutics - AdisInsight
37. Miricorilant - Corcept Therapeutics - AdisInsight
38. Nadolol - Invion - AdisInsight
39. Neboglamine - AdisInsight
40. NNC0194 0499 - AdisInsight
41. NS 2359 - AdisInsight
42. OMS 405 - AdisInsight
43. Pemvidutide - Altimmune - AdisInsight
44. SYNP 101 - AdisInsight
45. Selonabant - Anebulo Pharmaceuticals - AdisInsight
46. Sunobinop - Imbrium Therapeutics/Shionogi - AdisInsight
47. Cocaine abuse vaccine TA-CD - AdisInsight
48. TMP 301 - AdisInsight
49. Zolunicant - Mindmed - AdisInsight
50. Dexmedetomidine - BioXcel Therapeutics - AdisInsight
51. Ibogaine - Atai Beckley/DemeRx - AdisInsight
52. 5-Methoxy 2-aminoindane - Clearmind Medicine - AdisInsight
53. PT 00114 - AdisInsight
54. AZD 4041 - AdisInsight
55. BI 1356225 - AdisInsight
56. C4X 3256 - AdisInsight
57. Cebranopadol - Tris Pharma - AdisInsight
58. Dimethyltryptamin/harmine - Reconnect Labs - AdisInsight
59. DPI 125 - AdisInsight
60. Ibuprofen/ketotifen - Sen-Jam Pharmaceutical - AdisInsight
61. Icalcaprant - Cerevel Therapeutics - AdisInsight
62. KNX 100 - AdisInsight
63. Delving into the Latest Updates on KNX-100 with Synapse
64. "Combatting addiction with 'the love hormone'". sponsored.chronicle.com. 3 November 2021. Retrieved 12 January 2026.
65. Mavoglurant - STALICLA - AdisInsight
66. MEB 1170 - AdisInsight
67. Michael Haichin (2024). "Psychedelics Drug Development Tracker". Psychedelic Alpha. Retrieved 29 January 2025.
68. MST 01 - AdisInsight
69. Nalmefene - Avior Bio - AdisInsight
70. Naltrexone implantable pellets - BioCorRx - AdisInsight
71. NRS 033 - AdisInsight
72. OMS 527 - AdisInsight
73. Psilocybin - MycoMedia Life Sciences - AdisInsight
74. Smoking cessation therapeutics - Astraea Therapeutics - AdisInsight
75. SXC 2023 - AdisInsight
76. Tezampanel - Proniras - AdisInsight
77. TMP 301 - AdisInsight
78. AM 510 - Aion Medicines - AdisInsight
79. ATI 1013 - AdisInsight
80. CTRX 1001 - AdisInsight
81. CTRX 2001 - AdisInsight
82. Cyclobenzaprine hydrochloride - Tonix Pharmaceuticals - AdisInsight
83. Cyproheptadine/Prazosin - Kinnov Therapeutics - AdisInsight
84. N N dimethyltryptamine - Entheon Biomedical - AdisInsight
85. "EQUULUS Therapeutics". EQUULUS Therapeutics. Retrieved 17 February 2025.
86. Flumazenil + naloxone transdermal patch - MESOX - AdisInsight
87. GM 3009 - AdisInsight
88. INDV 1000 - AdisInsight
89. LPH 48 - AdisInsight
90. "Delving into the Latest Updates on LPH-48 with Synapse". synapse.patsnap.com.
91. "FAQ – Lophora". www.lophora.com. November 22, 2023.
92. M 101 - AdisInsight
93. 5-Methoxy 2-aminoindane - Clearmind Medicine - AdisInsight
94. Metyrapone/oxazepam - Embera - AdisInsight
95. 3,4-Methylenedioxymethamphetamine microneedle patch - PharmaTher/Revive Therapeutics - AdisInsight
96. Naltrexone controlled-release - BioCorRx - AdisInsight
97. Nicotine degrading enzyme - Antidote Therapeutics - AdisInsight
98. PPL 138 - AdisInsight
99. PSIL 001 - AdisInsight
100. "Psilera's New Compounds Show Potential for Significant Treatment Improvement in Depression and Neurodegenerative Disorders". Psychedelic Alpha. August 10, 2022.
101. "PSIL 002 - AdisInsight". adisinsight.springer.com.
102. "Psilera Confirms PSIL-002, A New DMT Derivative, is Well-Tolerated and Non-Hallucinogenic from In Vi - BioFlorida, Inc". www.bioflorida.com.
103. Psilacetin - Psilera - AdisInsight
104. Pudafensine - Initiator Pharma - AdisInsight
105. Research programme: psychedelic-based neurological therapeutics - Psilera - AdisInsight
106. Research programme: psychoplastogen therapeutics - Collaborations Pharmaceuticals - AdisInsight
107. "Tactogen Inc – Pipeline". Tactogen Inc. 8 February 2021. Retrieved 29 January 2025.
108. VS 01 - AdisInsight
109. "Arcadia Medicine". Arcadia Medicine.
110. Ibogaine - Biomind Labs - AdisInsight
111. LSR 2000 - AdisInsight
112. MYCO 004 - AdisInsight
113. "Delving into the Latest Updates on MYCO-004 with Synapse". synapse.patsnap.com.
114. Mydecine Innovations Group (7 April 2021). "Mydecine Announces Four Lead Novel Drug Candidates and Prepares for Pre-IND Meetings with the FDA and Health Canada To Prepare For Human Clinical". GlobeNewswire News Room (Press release).
115. Research programme: Ibogaine derivatives - MindMed/Nextage Therapeutics - AdisInsight
116. Research programme: monoclonal antibody therapeutics - CounterX Therapeutics - AdisInsight
117. Research programme: psychedelic and empathogenic compounds subcutaneous - Bexson Biomedical - AdisInsight
118. Substance-related disorders therapeutics - Tessara Therapeutics/Xylo Bio/University of Sydney - AdisInsight
119. VVZ 2471 - AdisInsight
120. Nicotine orally-dissolving film - NAL Pharma - AdisInsight
121. AP 002 - AdisInsight
122. AP 005 - AdisInsight
123. Varenicline implant - Shenzhen ScienCare Pharmaceutical - AdisInsight
124. AD 6626 - AdisInsight
125. AM 6527 - AdisInsight
126. Amitifadine - AdisInsight
127. Arbaclofen extended release - RVL Pharmaceuticals - AdisInsight
128. BMB 101 - AdisInsight
129. Bupropion/mecamylamine - Cary Pharmaceuticals - AdisInsight
130. Cannabidiol - Zynerba Pharmaceuticals - AdisInsight
131. CM 1212 - AdisInsight
132. CPP 115 - AdisInsight
133. CT 044 analogues - CERSCI Therapeutics - AdisInsight
134. CX 717 - AdisInsight
135. Cyproheptadine/Prazosin - Kinnov Therapeutics - AdisInsight
136. DCR AUD - AdisInsight
137. N N dimethyltryptamine - Entheon Biomedical - AdisInsight
138. GLWL 01 - AdisInsight
139. GSK 598809 - AdisInsight
140. GSK 1521498 - AdisInsight
141. GTS 21 - AdisInsight
142. Icalcaprant - Cerevel Therapeutics - AdisInsight
143. Levodopa - Acorda Therapeutics - AdisInsight
144. Mazindol controlled release - NewcelX - AdisInsight
145. Methylenedioxymetamfetamine - Mindmed - AdisInsight
146. Mifepristone - Corcept Therapeutics - AdisInsight
147. Modafinil oral - D&A Pharma - AdisInsight
148. Naloxone nasal spray - Adapt Pharma/Opiant Pharmaceuticals - AdisInsight
149. Nalmefene implant - Titan Pharmaceuticals - AdisInsight
150. Naloxone gel - Mucodel - AdisInsight
151. Nicotine abuse vaccine - Independent Pharmaceutica - AdisInsight
152. CVSI 007 - AdisInsight
153. Noribogaine derived therapeutic - MindMed/Nextage Therapeutics - AdisInsight
154. OMS 405 - AdisInsight
155. Ondansetron - ADial Pharmaceuticals - AdisInsight
156. Ondansetron/topiramate - AdisInsight
157. Ondelopran - R-Pharm - AdisInsight
158. PF 5402536 - AdisInsight
159. Pomaglumetad methionil - Denovo Biopharma/Eli Lilly and Company - AdisInsight
160. PPL 103 - AdisInsight
161. Pregnenolone methyl ether - Mapreg - AdisInsight
162. Psilocybin - Mydecine Innovations Group - AdisInsight
163. PT 150 - AdisInsight
164. Research programme: alcoholism therapeutics - ADial Pharmaceuticals - AdisInsight
165. Research programme: allosteric modulators - Addex Therapeutics - AdisInsight
166. Research programme: GPCR modulators - Nxera Pharma - AdisInsight
167. Research programme: nociceptin receptor agonists - Astraea Therapeutics - AdisInsight
168. Research programme: smoking cessation therapies - Ophidion - AdisInsight
169. Research programme: tryptamine based therapeutics - PsyBio Therapeutics - AdisInsight
170. Saracatinib - AstraZeneca - AdisInsight
171. SBP 9330 - AdisInsight
172. SEL 068 - AdisInsight
173. Serdexmethylphenidate - Zevra Therapeutics - AdisInsight
174. TRV 734 - AdisInsight
175. VDM 001 - AdisInsight
176. Zolunicant - Mindmed - AdisInsight
177. Dexmedetomidine - BioXcel Therapeutics - AdisInsight
178. Tetrodotoxin - Dogwood therapeutics - AdisInsight
179. ABT 436 - AdisInsight
180. Adrogolide - AdisInsight
181. ADX 629 - AdisInsight
182. ADX 10061 - AdisInsight
183. Anatabine - AdisInsight
184. ANS 6637 - AdisInsight
185. Arbaclofen placarbil - Indivior - AdisInsight
186. ASP 8062 - AdisInsight
187. Aticaprant - Johnson & Johnson Innovative Medicine - AdisInsight
188. Azasetron - AdisInsight
189. AZD 4041 - AdisInsight
190. Baclofen/samidorphan - AdisInsight
191. Befloxatone - AdisInsight
192. BP 897 - AdisInsight
193. BR 9003 - AdisInsight
194. BTRX 246040 - AdisInsight
195. Buprenorphine/naloxone - National Resilience - AdisInsight
196. Buprenorphine/samidorphan - Alkermes - AdisInsight
197. Synthetic cannabidiol - Benuvia Therapeutics/Radius Health - AdisInsight
198. CVL 936 - AdisInsight
199. CX 1739 - AdisInsight
200. CYB 003 - AdisInsight
201. CYB 004 - AdisInsight
202. Dianicline - AdisInsight
203. Drinabant - Opiant Pharmaceuticals - AdisInsight
204. Ecopipam - Emalex Biosciences - AdisInsight
205. Eglumetad - AdisInsight
206. Elinzanetant - Bayer - AdisInsight
207. Femoxetine - AdisInsight
208. Gabapentin enacarbil - Arbor Pharmaceuticals - AdisInsight
209. Gepirone - Fabre-Kramer Pharmaceuticals - AdisInsight
210. Istradefylline - Kyowa Kirin - AdisInsight
211. ITI 333 - AdisInsight
212. JNJ 39393406 - AdisInsight
213. JZP 150 - AdisInsight
214. Lisdexamfetamine - Shionogi/Takeda - AdisInsight
215. Lorcaserin - Eisai Inc - AdisInsight
216. Manifaxine - AdisInsight
217. Mavoglurant - STALICLA - AdisInsight
218. Nalmefene oral - Lundbeck A/S - AdisInsight
219. Nepicastat oral- Asieris Pharmaceuticals - AdisInsight
220. Neramexane - Merz Pharma - AdisInsight
221. NIC 002 - AdisInsight
222. Hoogsteder PH, Kotz D, van Spiegel PI, Viechtbauer W, Brauer R, Kessler PD, Kalnik MW, Fahim RE, van Schayck OC (December 2012). "The efficacy and safety of a nicotine conjugate vaccine (NicVAX®) or placebo co-administered with varenicline (Champix®) for smoking cessation: study protocol of a phase IIb, double blind, randomized, placebo controlled trial". BMC Public Health. 12 1052. doi: 10.1186/1471-2458-12-1052 . PMC   3547752 . PMID   23216646.
223. Hoogsteder PH, Kotz D, van Spiegel PI, Viechtbauer W, van Schayck OC (August 2014). "Efficacy of the nicotine vaccine 3'-AmNic-rEPA (NicVAX) co-administered with varenicline and counselling for smoking cessation: a randomized placebo-controlled trial". Addiction. 109 (8): 1252–1259. doi:10.1111/add.12573. PMID   24894625.
224. Nornicotine - AdisInsight
225. NS 2359 - AdisInsight
226. NYX 783 - AdisInsight
227. OREX 1019 - AdisInsight
228. OREX 1038 - AdisInsight
229. Oxytocin intranasal - Vyera Pharmaceuticals - AdisInsight
231. Rimonabant - AdisInsight
233. RTI 113 - AdisInsight
234. Samidorphan - AdisInsight
235. Sembragiline - AdisInsight
236. Serlopitant - VYNE Therapeutics - AdisInsight
237. Surinabant - AdisInsight
238. Celtic Pharma: The Portfolio: TA-NIC
239. Tradipitant - Vanda Pharmaceuticals - AdisInsight
240. Verucerfont - GlaxoSmithKline - AdisInsight
241. Vigabatrin - sanofi-aventis - AdisInsight
242. Banks ML, Bauer CT, Blough BE, Rothman RB, Partilla JS, Baumann MH, Negus SS (June 2014). "Abuse-related effects of dual dopamine/serotonin releasers with varying potency to release norepinephrine in male rats and rhesus monkeys". Experimental and Clinical Psychopharmacology. 22 (3): 274–284. doi:10.1037/a0036595. PMC   4067459 . PMID   24796848.
243. Long-lasting treatment drug could slow the opioid crisis
244. University awarded $12 million to further develop opioid use disorder drug Science & Medicine: UT Health San Antonio develops a drug to prevent opioid overdose and discourage relapse
245. Woods JH, Lewis JW, Winger G, Butelman E, Broadbear J, Zernig G (1995). "Methoclocinnamox: a mu partial agonist with pharmacotherapeutic potential for heroin abuse". NIDA Res Monogr. 147: 195–219. PMID   8742788.
246. Liu-Chen LY, Huang P (September 2025). "KOR agonists for the treatment and/or prevention of opioid use disorder and cocaine use disorder". Pharmacol Biochem Behav. 254 174056. doi:10.1016/j.pbb.2025.174056. PMID   40588011.
247. Havel V, Kruegel AC, Bechand B, McIntosh S, Stallings L, Hodges A, Wulf MG, Nelson M, Hunkele A, Ansonoff M, Pintar JE, Hwu C, Ople RS, Abi-Gerges N, Zaidi SA, Katritch V, Yang M, Javitch JA, Majumdar S, Hemby SE, Sames D (September 2024). "Oxa-Iboga alkaloids lack cardiac risk and disrupt opioid use in animal models". Nat Commun. 15 (1) 8118. Bibcode:2024NatCo..15.8118H. doi:10.1038/s41467-024-51856-y. PMC   11415492 . PMID   39304653.
248. "Delving into the Latest Updates on SR-17018 with Synapse". Synapse. 10 January 2026. Retrieved 13 January 2026.
249. Grim TW, Schmid CL, Stahl EL, Pantouli F, Ho JH, Acevedo-Canabal A, Kennedy NM, Cameron MD, Bannister TD, Bohn LM (January 2020). "A G protein signaling-biased agonist at the μ-opioid receptor reverses morphine tolerance while preventing morphine withdrawal". Neuropsychopharmacology. 45 (2): 416–425. doi:10.1038/s41386-019-0491-8. PMC   6901606 . PMID   31443104.
250. "This Week's Focus: Monitoring Emerging New Psychoactive Substances". National Drug Early Warning System (NDEWS). 14 November 2025. Retrieved 31 December 2025.
251. Buprenorphine depot - Camurus - AdisInsight
252. Buprenorphine extended-release - Indivior - AdisInsight
253. Buprenorphine/naloxone sublingual - Indivior - AdisInsight
254. Methadone - Recordati - AdisInsight
255. Nalmefene oral - Lundbeck A/S - AdisInsight
256. Nalmefene nasal spray - Indivior - AdisInsight
257. Naloxone injection - kaleo - AdisInsight
258. Naloxone hydrocloride intranasal spray - Kindeva Drug Delivery - AdisInsight
259. Naloxone intranasal spray - Hikma Pharmaceuticals - AdisInsight
260. Naloxone multidose nasal spray - Emergent BioSolutions - AdisInsight
272. Honey BL, Benefield RJ, Miller JL, Johnson PN (September 2009). "Alpha2-receptor agonists for treatment and prevention of iatrogenic opioid abstinence syndrome in critically ill patients". Ann Pharmacother. 43 (9): 1506–1511. doi:10.1345/aph.1M161. PMID   19690220.
273. Kuszmaul AK, Palmer EC, Frederick EK (2020). "Lofexidine versus clonidine for mitigation of opioid withdrawal symptoms: A systematic review". J Am Pharm Assoc (2003). 60 (1): 145–152. doi:10.1016/j.japh.2019.10.004. PMID   31791720.
274. Fluyau D, Revadigar N, Manobianco BE (May 2018). "Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation". Ther Adv Psychopharmacol. 8 (5): 147–168. doi:10.1177/2045125317753340. PMC   5896864 . PMID   29713452.
275. Cheng YC, Huang YC, Huang WL (November 2020). "Gabapentinoids for treatment of alcohol use disorder: A systematic review and meta-analysis". Hum Psychopharmacol. 35 (6): 1–11. doi:10.1002/hup.2751. PMID   32667088.
276. Moore MD, Moore RK, Alzghari SK (December 2025). "Ibogaine: Revisiting an Ancient Alkaloid for Modern Opioid Dependence". Subst Use Misuse: 1–3. doi:10.1080/10826084.2025.2604213. PMID   41404929.
277. Stead LF, Hughes JR (February 2012). "Lobeline for smoking cessation". Cochrane Database Syst Rev. 2012 (2) CD000124. doi:10.1002/14651858.CD000124.pub2. PMC   7043274 . PMID   22336780.
278. Lancaster T, Stead LF (2000). "Mecamylamine (a nicotine antagonist) for smoking cessation". Cochrane Database Syst Rev. 1998 (2) CD001009. doi:10.1002/14651858.CD001009. PMC   7271835 . PMID   10796584.
279. Pajai DD, Paul P, Reche A (February 2023). "Pharmacotherapy in Tobacco Cessation: A Narrative Review". Cureus. 15 (2) e35086. doi: 10.7759/cureus.35086 . PMC   10023046 . PMID   36938244.
280. Kupats E, Vrublevska J, Zvejniece B, Vavers E, Stelfa G, Zvejniece L, Dambrova M (September 2020). "Safety and Tolerability of the Anxiolytic and Nootropic Drug Phenibut: A Systematic Review of Clinical Trials and Case Reports". Pharmacopsychiatry. 53 (5): 201–208. doi:10.1055/a-1151-5017. PMID   32340063.
281. Wittenkeller L, Gudelsky G, Winhusen TJ, Amato D (September 2025). "Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology". Br J Pharmacol bph.70181. doi:10.1111/bph.70181. PMID   40891276.
282. Marcus O, Rush B (January 2026). "Psychedelics for the Treatment of Substance Use Disorders: A Narrative Review of the Literature". Subst Use Addctn J. 47 (1): 279–296. doi:10.1177/29767342251351123. PMID   40882971.
283. Yaden DB, Berghella AP, Hendricks PS, Yaden ME, Levine M, Rohde JS, Nayak S, Johnson MW, Garcia-Romeu A (January 2024). "IUPHAR-review: The integration of classic psychedelics into current substance use disorder treatment models". Pharmacol Res. 199 106998. doi:10.1016/j.phrs.2023.106998. PMID   38029805.
284. Manhapra A, Chakraborty A, Arias AJ (2019). "Topiramate Pharmacotherapy for Alcohol Use Disorder and Other Addictions: A Narrative Review". J Addict Med. 13 (1): 7–22. doi:10.1097/ADM.0000000000000443. PMID   30096077.

External links

• AdisInsight - Springer